EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Exit Interviews to Understand Meaningful Change from the Patient Perspective in a Clinical Study of Dupilumab for the Treatment of Chronic Inducible Cold Urticaria

Ella Brookes iD, Ufuk Coşkun, Christina O'Donnell, Efstathios Zikos, Renata Martincova, Jingdong Chao, Mohana Giruparajah, Beverly Romero

The Patient - Patient-Centered Outcomes Research · 2025

DOI: 10.1007/s40271-025-00754-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Patient - Patient-Centered Outcomes Research, 2025. Verfasst von Ella Brookes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, 410 Thames Valley Park Drive, Reading, RG6 1PT, UK. ella.brookes@sanofi.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Patient Reported Outcome Measures, Chronic Urticaria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study uses clinical trial exit interviews to understand patients' experience of meaningful change with respect to patient-reported outcomes and in order to confirm the content validity of some items from selected trial patient-reported outcomes (Urticaria Control Test [UCT], Cold Urticaria Activity Score [ColdUAS], Patient Global Impression of Severity [PGIS], Patient Global Impression of Change [PGIC]). Clinical trial exit interviews are an effective way to generate qualitative meaningful change insights. However, there is lack of data to provide an understanding of meaningful improvement from the chronic inducible cold urticaria patient perspective. METHODS: We conducted a cross-sectional, double-blind, stand-alone exit interview study intended to recruit participants aged 12-80 years with cold urticaria across centers in Argentina, Canada, USA, and Germany participating in LIBERTY-CINDU CUrIADS (EudraCT: 2020-003756-33), which analyzed the efficacy of dupilumab versus placebo. Exit interviews were conducted within 2 weeks of the end of treatment. RESULTS: Participants (N = 15) reported symptoms including rash/redness, itch, hives, swelling, burning, and pain. The study established patient-defined thresholds for meaningful improvement: approximately two response options for UCT items, slightly fewer than two response options for ColdUAS items, and 1-2 category changes on PGIS/PGIC. Most participants reporting symptom improvement found it meaningful, with satisfaction being related to the degree of symptom relief. Notably, patients distinguished between a general symptom change and clinically meaningful change. CONCLUSIONS: Exit interviews revealed key insights into patients' experiences with cold urticaria. Despite some limitations, including recruitment challenges and an all-female adult participant pool, the study provided valuable evidence for understanding meaningful improvement in cold urticaria treatment from the patient perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPatient Reported Outcome MeasuresChronic UrticariaHumansFemaleMiddle AgedMaleAdultAgedDouble-Blind MethodCross-Sectional StudiesAdolescentYoung AdultAged, 80 and overChildInterviews as TopicCanadaArgentinaGermanyCold Urticaria

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Sanofi, 410 Thames Valley Park Drive, Reading, RG6 1PT, UK. ella.brookes@sanofi.com.
  • ICON Clinical Research, Blue Bell, PA, USA.
  • Sanofi, Paris, France.
  • Sanofi, Prague, Czech Republic.
  • Regeneron Pharmaceuticals Inc., Sleepy Hollow, NY, USA.
  • ICON Clinical Research, Dublin, Ireland.

ORCID-Profile: Ella Brookes

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals

Zitieren

APA

Brookes, E., Coşkun, U., O'Donnell, C., Zikos, E., Martincova, R., Chao, J., Giruparajah, M., & Romero, B. (2025). Exit Interviews to Understand Meaningful Change from the Patient Perspective in a Clinical Study of Dupilumab for the Treatment of Chronic Inducible Cold Urticaria. The Patient - Patient-Centered Outcomes Research. https://doi.org/10.1007/s40271-025-00754-6

Vancouver

Brookes E, Coşkun U, O'Donnell C, Zikos E, Martincova R, Chao J, et al. Exit Interviews to Understand Meaningful Change from the Patient Perspective in a Clinical Study of Dupilumab for the Treatment of Chronic Inducible Cold Urticaria. The Patient - Patient-Centered Outcomes Research. 2025. doi:10.1007/s40271-025-00754-6

BibTeX
@article{Brookes2025,
  author = {Brookes, Ella and Coşkun, Ufuk and O'Donnell, Christina and Zikos, Efstathios and Martincova, Renata and Chao, Jingdong and Giruparajah, Mohana and Romero, Beverly},
  title = {Exit Interviews to Understand Meaningful Change from the Patient Perspective in a Clinical Study of Dupilumab for the Treatment of Chronic Inducible Cold Urticaria},
  journal = {The Patient - Patient-Centered Outcomes Research},
  year = {2025},
  doi = {10.1007/s40271-025-00754-6}
}
Kostenlos starten →